« Return to News | Clinical Intelligence

Lexicon’s LX411 enhances DPP-4 inhibitor in type 2 diabetics

Friday, January 13, 2012 12:09 PM

LX4211, a novel sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, was proven to enhance the affects of widely prescribed diabetes drug sitagliptin, a DDP-4 (dipeptidyl peptidase) inhibitor, reported Lexicon Pharmaceuticals.

Results of the study showed 18 patients with type 2 diabetes given single doses of LX4211 in combination with sitagliptin produced lower blood glucose levels after meals (postprandial) as compared to being treated with sitagliptin alone.

"Alone, LX4211 produces rapid improvement in postprandial blood glucose by delaying intestinal glucose absorption and increasing urinary glucose excretion,” said Dr. Pablo Lapuerta, senior vice president of clinical development and chief medical officer at Lexicon. “When combined, the two agents produce enhanced benefits on blood glucose, insulin, GLP-1 and PYY relative to sitagliptin alone, suggesting these agents work together and could provide additional benefits for patients with type 2 diabetes."

The study was design to assess pharmacodynamic parameters, including postprandial glucose, insulin, total and active GLP-1, PYY and urinary glucose excretion.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.